to the opportunity to present our data on prevalence, treatment patterns, and long-term clinical outcomes of real-world patients with EGFR-positive resected stage 1b23a non-small-cell lung cancer today at World Lung Conference 2021. These are my disclosures. The phase three ADORA trial showed significant disease-free survival benefit for adjuvant-osin-mergineb compared to placebo in resected stage 1b23a EGFR-mutated non-small-cell lung cancers. However, reflex testing for EGFR in early stages has not been established across centers and therefore true prevalence estimations and information on treatment patterns and outcomes of these patients in a real-world setting so far is not well-documented. The aim of this analysis was to estimate EGFR mutation prevalence, treatment patterns, and long-term outcomes in early stage 1b23a resected non-squamous non-small-cell lung cancer patients in a real-world setting. All patients with completely resected non-squamous stage 1b23a non-small-cell lung cancer seen at the Princess Margaret Cancer Center between 2012 and 2018 were included and clinical demographic treatment and survival data were collected. Patients who had received neoadjuvant treatment were excluded from the analysis. For prevalence estimations, only data from patients diagnosed between 2014 and 2018 were included based on the fact that in 2014, reflex testing across all stages, including early stage patients had been established at the Princess Margaret Hospital and therefore allowing true prevalence estimation in that board of patients. In 224 patients with resected stage 1b23a non-squamous non-small-cell lung cancer identified and included into the analysis between 2014 and 2018 and therefore after reflex testing was established, prevalence of EGFR positive patients was 32% and this was quite evenly distributed across stages. As expected, prevalence was significantly higher in female and never-smoker and Asian patients. On the right side, you see an overview of the baseline characteristics of all patients that are identified with resected stage 1b23a EGFR positive disease at Princess Margaret Hospital between 2012 and 2018 and therefore including patients that were identified before reflex testing was actually established. The identified 104 resected patients and baseline characteristics, again, as expected, were quite similar with mainly females, never-smokers and 50% Asians included. All the further analysis will always base on that board of 104 patients. Disease-free survival in the overall cohort was 29-month and as you can see on the right side was not reached for stage 1b patients, 26-month for stage 2 and 15.5-month for stage 3a patients. As you can see in the table below, where 61% of stage 1b patients remained disease-free at seven years, that percentage was significantly lower for stage 2 and 3a patients where it was only 8% of patients remaining disease-free at seven years. Overall survival in the overall cohort, again, was not reached and the same holds true as you can see on the right side for stage 1b patients. And actually, overall survival is quite similar for stage 2 and 3a patients with 71.2-month for stage 2 and 79.5-month for stage 3a patients. Then analyzing disease-free survival and overall survival depending on type of EGFR mutation present, we did not see a significant difference neither with regards to disease-free survival nor overall survival in patients with common compared to uncommon EGFR mutations. In summary, clinical demographic characteristics and early survival outcomes of patients with EGFR positive stage 1b to 3a, non-small cell lung cancer seen at the Princess Margaret Cancer Center were very similar to the placebo control arm of Adora trial. There is the probability for stage 1b patients to remain relapse-free at seven years with 60%. The vast majority of stage 2 and 3a patients had recurred at seven years. No significant difference in disease-free survival and overall survival between patients with common compared to uncommon mutations was observed. However, number of patients with uncommon mutations was overall very low. With the longer follow-up available in our cohort, we do anticipate that the placebo-controlled arm of Adora will also demonstrate growing numbers of recurrences and deaths. Thank you very much for your attention.

EGFR-positive lung cancer

prevalence

treatment patterns

long-term outcomes

real-world patients